2PQ Stock Overview
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Organogenesis Holdings Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.28 |
| 52 Week High | US$4.24 |
| 52 Week Low | US$1.84 |
| Beta | 1.57 |
| 1 Month Change | -11.63% |
| 3 Month Change | -24.00% |
| 1 Year Change | 21.28% |
| 3 Year Change | -86.82% |
| 5 Year Change | -63.21% |
| Change since IPO | -69.88% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2PQ | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 5.6% | 2.2% | -1.0% |
| 1Y | 21.3% | -22.2% | 2.2% |
Return vs Industry: 2PQ exceeded the German Biotechs industry which returned -22.4% over the past year.
Return vs Market: 2PQ exceeded the German Market which returned 2% over the past year.
Price Volatility
| 2PQ volatility | |
|---|---|
| 2PQ Average Weekly Movement | 11.7% |
| Biotechs Industry Average Movement | 5.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 2PQ's share price has been volatile over the past 3 months.
Volatility Over Time: 2PQ's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1985 | 862 | Gary Gillheeney | organogenesis.com |
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company’s advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold.
Organogenesis Holdings Inc. Fundamentals Summary
| 2PQ fundamental statistics | |
|---|---|
| Market cap | €306.63m |
| Earnings (TTM) | €4.59m |
| Revenue (TTM) | €402.34m |
66.8x
P/E Ratio0.8x
P/S RatioIs 2PQ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2PQ income statement (TTM) | |
|---|---|
| Revenue | US$433.14m |
| Cost of Revenue | US$106.48m |
| Gross Profit | US$326.66m |
| Other Expenses | US$321.71m |
| Earnings | US$4.95m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 09, 2024
| Earnings per share (EPS) | 0.037 |
| Gross Margin | 75.42% |
| Net Profit Margin | 1.14% |
| Debt/Equity Ratio | 23.8% |
How did 2PQ perform over the long term?
See historical performance and comparison